Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits, as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; and PBGENE-DMD (Excision) for the treatment of Duchenne muscular dystrophy. In addition, the company develops PBGENE-3243 for the treatment of m.3243 associated mitochondrial diseases; and iECURE-OTC (Insertion) for ornithine transcarbamylase deficiency. It has collaboration agreements with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azercabtagene zapreleucel for autoimmune diseases and other indications; and iECURE, Inc., an ARCUS-mediated targeted gene insertion. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
Analyst Outlook | BMO Capital Markets maintains a Market Perform rating with a $34 price target, reflecting cautious optimism about the company's future prospects |
Competitive Edge? | Explore how Precision BioSciences aims to differentiate itself in the crowded gene editing market, with upcoming clinical readouts potentially validating its technology |
Financial Runway | With $140 million in cash, the company has funding until 2026, but faces challenges in improving investor sentiment amidst recent strategic shifts |
ARCUS Innovation | Precision BioSciences' proprietary gene editing platform shows promise in HBV treatment, with clinical trials on the horizon for its lead program PBGENE-HBV |
Metrics to compare | DTIL | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipDTILPeersSector | |
|---|---|---|---|---|
P/E Ratio | −4.0x | 7.9x | −0.5x | |
PEG Ratio | 0.01 | −0.34 | 0.00 | |
Price / Book | 2.0x | 2.9x | 2.6x | |
Price / LTM Sales | 5.4x | 2.7x | 3.2x | |
Upside (Analyst Target) | 238.9% | 428.4% | 47.6% | |
Fair Value Upside | Unlock | 30.3% | 6.1% | Unlock |